Marine Microalgae Lipid Nanoparticles for Transdermal Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticle carriers, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), face limitations in capacity for encapsulated active substances and stability during storage, particularly in transdermal applications, where particle size and composition affect penetration and stability.
Innovation Solution
A method for synthesizing lipid nanoparticles using marine microalgae oil from Schizochytrium and diatoms' lipids, employing a high-speed homogenization process with specific surfactants and lipids to achieve particles of 100-300 nm size, enhancing stability and encapsulation capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If solid lipid nanoparticles (SLN) are used as carriers, then the structure is simple and manufacturing is easier, but the capacity for encapsulated active substance is low and physical stability deteriorates during storage
Solution Approach 1:
The patent uses composite materials by combining solid lipids with liquid lipids to create nanostructured lipid carriers (NLC). This composite approach allows the system to maintain the ease of manufacture of solid lipids while gaining the enhanced encapsulation capacity and physical stability provided by the liquid lipid component, effectively resolving the contradiction between manufacturing simplicity and storage stability.
Solution Approach 2:
The patent applies parameter changes by modifying the lipid matrix composition from pure solid lipids to a mixture of solid and liquid lipids. This parameter modification (adding liquid lipid phase) transforms the system's properties, enabling improved encapsulation capacity and physical stability during storage while maintaining relatively simple manufacturing processes.
2Ease of manufacture
If solid lipid nanoparticles (SLN) are used as carriers, then the manufacturing process is simpler, but the capacity for encapsulated active substance is low
Solution Approach 1:
By creating a composite lipid system combining solid and liquid lipids, the patent achieves higher encapsulation capacity without significantly complicating the manufacturing process. The liquid lipid component creates additional spaces and improves matrix structure for active substance incorporation, resolving the contradiction between manufacturing simplicity and encapsulation capacity.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the lipid matrix by incorporating liquid lipids, which increases the available volume and improves the matrix's ability to encapsulate active substances. This parameter change enables higher encapsulation capacity while maintaining a relatively straightforward manufacturing approach.
3Length of moving object
If particle size is reduced to 100-300 nm for transdermal penetration, then penetration ability improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies preliminary action by pre-mixing the lipid components and active substances before the homogenization step. This preliminary preparation ensures uniform distribution of components, which facilitates the subsequent formation of uniform nanoparticles at the target size range (100-300 nm) without requiring excessively precise manufacturing control.
Solution Approach 2:
The patent uses parameter changes in the form of optimized homogenization conditions (speed, time, temperature) and lipid composition to achieve the target particle size range. By carefully controlling these parameters, the system produces nanoparticles of 100-300 nm with acceptable polydispersity, balancing penetration ability with manufacturing feasibility.
Data Source
Figure 1~2
AI summary
The subject of the invention is a method of obtaining lipid nanoparticles, synthesised on the basis of oil from marine microalgae (Schizochytrium) and lipids obtained from diatoms (Halamphora), characterised by a particle size in the range of 100-300 nm. A manner of obtaining lipid nanoparticles synthesised on the basis of marine microalgae oil (Schizochytrium) and lipids obtained from diatoms (Halamphora) using a HSH method, consisting of a mixture containing glycerol stearate (Imwitor 900K) in an amount of 1-5 g, advantageously 2.5 g, cetyltrimethylammonium bromide (CTAB) in an mount of 0.1-0.8 g advantageously 0.4 g, lipids extracted earlier from Halamphora diatoms in an amount of 0.2-1 g advantageously 0.6 g, oil from marine microalgae (Schizochytrium) in an amount of 0.4-1.2 g advantageously 0.8 g and glycerol in an amount of 5-15 g advantageously 10 g, to a temperature above 75°C with continuous mixing at a speed of 400-600 rpm advantageously 600 rpm until an uniform consistence is obtained, then the mixture is subjected to pre-homogenisation at a speed of 8 000-24 000 rpm advantageously 13 500 rpm for 5-20 seconds, advantageously 10 seconds, afterwards to the homogenised sample 1 ml of Tween 80 aqueous water solution heated to the temperature of 40°C at concentration of 10-60% w/w, advantageously 30% w/w is added and mixed at a speed of 400-600 rpm, advantageously 600 rpm for 0.5-2 minutes advantageously for 1 minute until a uniform consistency is obtained, then the sample is subjected to two-stage proper homogenisation: in the first stage at a speed of 13 500 - 24 000 rpm advantageously 20 500 rpm for 5-15 seconds, advantageously 10 seconds; in the second stage at a speed of 8 000-13 500 rpm advantageously 9,500 rpm for 5-15 seconds, advantageously 10 seconds, after which the obtained dispersion is added to 14-14.9 ml advantageously 14.3 ml of Tween 80 water solution at concentration of 10-60% w/w advantageously 30% w/w with continuous mixing at a speed of 350-550 rpm, advantageously 350 rpm and is mixed until the system cools down to room temperature, advantageously 25°C and until NLC type lipid nanoparticles are obtained, characterised with a particle size in the range of 100-300 nm.